Special Issue

Superbugs Unleashed: Global Challenges and Solutions for Extensively Drug-Resistant and Pan-Drug-Resistant Pathogens

Message from the Guest Editor

The global rise in extensively drug-resistant (XDR) and pan-drug-resistant (PDR) pathogens marks a critical turning point in the fight against infectious diseases. Once considered rare, these "superbugs" have now breached hospitals, communities, and even the food chain, challenging the very foundation of modern medicine. This Special Issue, "Superbugs Unleashed: Global Challenges and Solutions for Extensively Drug-Resistant and Pan-Drug-Resistant Pathogens", collates cutting-edge research, policy perspectives, and clinical strategies aimed at confronting one of the most pressing medical crises of our time. We explore the drivers behind antimicrobial resistance, including misuse in human and veterinary medicine, and examine emerging diagnostic tools, novel therapeutic options, and global stewardship efforts. This Special Issue welcomes all submissions related to the epidemiology, diagnosis, treatment, surveillance, and prevention of infections caused by drug-resistant pathogens, including original research articles, reviews, and opinion papers.

Guest Editor

Dr. Ionela-Larisa Miftode

1. Faculty of Medicine, University of Medicine and Pharmacy "Grigore T. Popa" of Iaşi, 700115 Iasi, Romania

2. Clinic of Infectious Diseases, "Sf. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania

Deadline for manuscript submissions

31 January 2026



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/241463

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

